This is a working overview of thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
== Awards and accolades == 1984 Elected Fellow of the National Academy of Clinical Biochemistry (now FADLM) 1988 Distinguished Scientist Award, (Clinical Ligand Assay Society) 1990-92 Co-Editor-in-Chief, Clinical Biochemistry 1996-97 President, International Clinical Ligand Assay Society 1998 Doctor of Medicine honoris causa (Leopold-Franzens-Universität Innsbruck, Austria) 1998 University of Louisville Symposium honoring the career of James L. Wittliff 2001 American Association for Clinical Chemistry (Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research) 2001 American Association for Clinical Chemistry (Hall of Fame recognition) 2002 Interagency Coordinating Committee on the Validation of Alternative Methods/ National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods- Expert Panel 2004 Goldsmith Research Excellence Award, American Cancer Society, Kentucky Division 2008 President's Award for Career Achievements: Outstanding Scholarship, Research and Creative Activity, University of Louisville 2011 Interagency Coordinating Committee on the Validation of Alternative Methods/ National Toxicology Program Independent Scientific Peer Review Panel for the Evaluation of the LUMI-CELL® ER (BG1Luc ER TA) Test Method 2012 The CPT Paul W. Peña Outstanding Alumni Award - San Marcos Academy, San Marcos, TX 2014 Morton K.
== Safety challenges == Because pyrolysis takes place at high temperatures which exceed the autoignition temperature of the produced gases, an explosion risk exists if oxygen is present. Careful temperature control is needed for pyrolysis systems, which can be accomplished with pyrolysis controller. Pyrolysis also produces various toxic gases, such as carbon monoxide. The greatest risk of fire, explosion, and release of toxic gases comes when the system is starting up and shutting down, operating intermittently, or during operational upsets. Inert gas purging is essential to manage inherent explosion risks. The procedure is not trivial and failure to keep oxygen out has led to accidents.
==== International Congress of Refrigeration ==== First held in 1908, the International Congress of Refrigeration of the IIR is a flagship event that converges industry and research. Covering all fields of refrigeration, the Congress, which takes place every four years, reunites key international stakeholders and provides perspectives on the future of the industry in line with sustainable development.
=== Operation Enduring Freedom – Philippines === OEF-P was established in 2002 to conduct what SOCOM history terms "full spectrum embedding and engagement"-focusing on long-term partnered operations with Philippine police and Army special operations and intelligence units as well as local units with the necessary skills to counter ASG and JI. Much of this work has fallen to 1st SFG. SOCPAC deployed a Joint Task Force-510 (JTF-510) to Zamboanga City on Mindanao, Philippines in January 2002 to prepare for the introduction of forces onto Basilan. From February to July 2002, 10 ODAs and 3 ODBs (Operational Detachment Bravos) of 1st SFG provided training, advice, and assistance to 15 Armed Forces of the Philippines (AFP) Infantry Battalions. Their mission on Basilan was to work through, with, and by AFP units to destroy the ASG organization on the island. The ODAs were prohibited from conducting combat operations and performing advisory tasks below the battalion level, the ODAs focused on denying ASG sanctuary by preparing the AFP to improve security operations by controlling lines of communication, improving the infrastructure for the local populace through Civil Affairs, and bolstering the government in the eyes of citizens through information operations. After completing operations by late summer 2002, JTF-510 departed Zamboanga. On 2 October 2002, a bombing at an open-air market outside the gate of Camp Enrile Malagutay in Zamboanga City killed a U.S. Special Forces soldier from A Company, 2nd Battalion, 1st SFG.
== External links == Army Regulation 611-1: Military Occupational Classification Structure Development and Implementation (December 2022). US Army MOS Titles & Codes, Enlisted Personnel, 15 November 1950 - Korean War-era list from Korean War Educator Foundation
Sources: en.wikipedia.org
The relative molecular mass (denoted Mr) of a substance, formerly also called molecular weight and abbreviated as MW, is the mass of one molecule of that substance, relative to the dalton (Da), which is equal to 1/12 the mass of one atom of 12C. Due to this relativity, the molecular mass of a substance is commonly referred to as the relative molecular mass, and denoted to Mr.
For example, the Ranunculaceae species, including Clematis and Ranunculus, produces an etaerio of achenes; Rubus species, including raspberry: an etaerio of drupelets; Calotropis species: an etaerio of follicles fruit; Annona species: an etaerio of berries. Some other broadly recognized species and their etaerios (or aggregations) are:
The availability of furikake in Japan increased starting shortly after September 1948, when Nissin Foods began to manufacture it on a large scale to address pervasive malnourishment. The product was commercialized on the basis that it provided a good source of protein and calcium. Furikake was made widely available as it was dispensed to those serving in the Japanese military starting in World War I. The term furikake was used generically to describe the product starting in 1959 with the formation of the National Furikake Association. Since 1959, furikake products are usually differentiated by their particular ingredients, such as salmon furikake and sesame-and-salt furikake. In the same year, Marumiya Foods developed "Noritama," a sweetened egg added to Kore Wa Umai which became popular as furikake for children. In 1963, Noritama with a sticker of 8 Man became explosively popular, and furikake was transformed from a luxury food for adults to a popular food for children. In 1970, Mishima Shokuhin marketed a new furikake, made by reusing the red shiso used to color pickled plums, under the product name Yukari. The name comes from the desire to create a connection ("縁" (yukari) in Japanese) with customers. In the 1980s, furikake became strongly associated with children's food, and its use rapidly declined after the age of 12. In 1989, Nagatanien began selling "furikake for adults" using ingredients with a luxurious taste and pungent flavor. The initial varieties were "Salmon," "Bonito," and "Wasabi."
Multiple types of internal border controls exist in the United States. While the American territories of Guam and the Northern Mariana Islands follow the same visa policy as the mainland, together, they also maintain their own visa waiver programme for certain nationalities. Since the two territories are outside the customs territory of the United States, there are customs inspections when travelling between them. The rest of the U.S. American Samoa has its own customs and immigration regulations, thus travelling between it and other American jurisdictions involves both customs and immigration inspections. The Virgin Islands are a special case: they fall within the American immigration zone and follow American visa policy, but are a customs-free territory. As a result, there are no immigration checks between the two, but travellers arriving in Puerto Rico or the American mainland directly from the Virgin Islands are subject to border control for customs inspection. The United States also maintains interior checkpoints, similar to those maintained by Bhutan, along its borders with Mexico and Canada, subjecting people to border controls even after they have entered the country. The Akwesasne nation; with territory in Ontario, Quebec, and New York; features several de facto internal border controls.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.